Literature DB >> 26136951

Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.

Chun-Wei Xu1, Gang Wang2, Wu-Long Wang3, Wen-Bin Gao2, Chuan-Jun Han4, Jing-Shan Gao5, Li-Ying Zhang1, Yang Li6, Lin Wang7, Yu-Ping Zhang8, Yu-Wang Tian1, Dong-Dong Qi2.   

Abstract

This study aimed to investigate the association of the mRNA expression of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene with that of thymidylate synthase (TYMS) in non-small cell lung cancer (NSCLC) tissues. Quantitative polymerase chain reaction was used to detect the expression of EML4-ALK fusion gene and TYMS mRNA in 257 cases of NSCLC. The positive rate of EML4-ALK fusion gene was 4.28% in the NSCLC tissues (11/257), and was higher in nonsmokers than in smokers (P<0.05); TYMS mRNA expression was detected in 63.42% (163/257) of cases. An association of the EML4-ALK fusion gene with TYMS expression was detected; a low expression level of TYMS mRNA was observed more frequently when the EML4-ALK fusion gene was present than when it was not detected (P<0.05). In conclusion, patients positive for the EML4-ALK fusion gene in NSCLC tissues are likely to have a low expression level of TYMS, and may benefit from the first-line chemotherapy drug pemetrexed.

Entities:  

Keywords:  EML4-ALK; individual treatment; molecular detection; non-small cell lung cancer; thymidylate synthase

Year:  2015        PMID: 26136951      PMCID: PMC4473652          DOI: 10.3892/etm.2015.2372

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

1.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex.

Authors:  E Chu; S M Copur; J Ju; T M Chen; S Khleif; D M Voeller; N Mizunuma; M Patel; G F Maley; F Maley; C J Allegra
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

Review 3.  The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.

Authors:  R B Diasio; M R Johnson
Journal:  Pharmacology       Date:  2000-09       Impact factor: 2.547

4.  Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy.

Authors:  Kazuyuki Kawakami; Francesco Graziano; Go Watanabe; Annamaria Ruzzo; Daniele Santini; Vincenzo Catalano; Renato Bisonni; Federica Arduini; Italo Bearzi; Stefano Cascinu; Pietro Muretto; Giuseppe Perrone; Carla Rabitti; Lucio Giustini; Giuseppe Tonini; Francesca Pizzagalli; Mauro Magnani
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 5.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

6.  The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Authors:  Daisy Wing-Sze Wong; Elaine Lai-Han Leung; Kimpton Kam-Ting So; Issan Yee-San Tam; Alan Dart-Loon Sihoe; Lik-Cheung Cheng; Kwok-Keung Ho; Joseph Siu-Kie Au; Lap-Ping Chung; Maria Pik Wong
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

7.  EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Kimie Nomura; Hironori Ninomiya; Michiyo Okui; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Toshiro Niki; Hiroyuki Mano; Yuichi Ishikawa
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

8.  A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.

Authors:  Henry L Gomez; Sergio L Santillana; Carlos S Vallejos; Raul Velarde; Juvenal Sanchez; Xinpeng Wang; Nancy L Bauer; Richard D Hockett; Victor J Chen; Clet Niyikiza; Axel R Hanauske
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 9.  Small cell lung cancer.

Authors:  Taimur Sher; Grace K Dy; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-03       Impact factor: 7.616

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  7 in total

Review 1.  Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes.

Authors:  Pascale Tomasini; Fabrice Barlesi; Celine Mascaux; Laurent Greillier
Journal:  Ther Adv Med Oncol       Date:  2016-05-09       Impact factor: 8.168

2.  KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

Authors:  Vienna Ludovini; Biagio Ricciuti; Francesca R Tofanetti; Clelia Mencaroni; Diana Giannarelli; Angelo Sidoni; Maria S Reda; Annamaria Siggillino; Sara Baglivo; Lucio Crinò; Guido Bellezza; Rita Chiari; Giulio Metro
Journal:  Mol Clin Oncol       Date:  2018-10-01

Review 3.  The impact of fusion genes on cancer stem cells and drug resistance.

Authors:  Saurav Panicker; Sivaramakrishnan Venkatabalasubramanian; Surajit Pathak; Satish Ramalingam
Journal:  Mol Cell Biochem       Date:  2021-06-07       Impact factor: 3.396

Review 4.  Targeted therapies and immunotherapy in non-small-cell lung cancer.

Authors:  D Cortinovis; M Abbate; P Bidoli; S Capici; S Canova
Journal:  Ecancermedicalscience       Date:  2016-06-23

5.  Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.

Authors:  Jaemin Jo; Se Hyun Kim; Yu Jung Kim; Juhyun Lee; Miso Kim; Bhumsuk Keam; Tae Min Kim; Dong Wan Kim; Dae Seog Heo; Jin Haeng Chung; Yoon Kyung Jeon; Jong Seok Lee
Journal:  Yonsei Med J       Date:  2018-03       Impact factor: 2.759

6.  What is Currently the Best for Adenocarcinoma without Driver Mutation?

Authors:  Cheol Kyu Park; In Jae Oh; Young Chul Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-06-19

7.  Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.

Authors:  Chun-Wei Xu; Wen-Xian Wang; Yan-Ping Chen; Yu Chen; Wei Liu; Li-Hua Zhong; Fang-Fang Chen; Wu Zhuang; Zheng-Bo Song; Xiao-Hui Chen; Yun-Jian Huang; Yan-Fang Guan; Xin Yi; Tang-Feng Lv; Wei-Feng Zhu; Jian-Ping Lu; Xiao-Jiang Wang; Yi Shi; Xian-Dong Lin; Gang Chen; Yong Song
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.